CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 12 enrolled
Drug / intervention
Lanadelumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04180163
NCT04180163Phase 3Completed
CompareCT.gov

A Phase 3 Multi-center, Open-label Study to Evaluate the Efficacy and Safety of Lanadelumab (SHP643) in Japanese Subjects With Hereditary Angioedema

Shire·interventional·Posted Nov 27, 2019·Updated Sep 30, 2022

In Brief

A Phase 3 clinical trial evaluating Lanadelumab for Hereditary Angioedema (HAE). Completed, enrolled 12 participants across 12 sites.

Detailed Summary

The purpose of this phase 3, open-label, multi-center study is to evaluate the safety and efficacy of lanadelumab in Japanese participants with HAE Type I or II.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHereditary Angioedema (HAE)
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedNov 27, 2019
Enrollment StartDec 12, 2019
Primary CompletionAug 26, 2021
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.6 years ago

Interventions

Lanadelumabdrug

Lanadelumab solution, SC